The Food and Drug Administration approved Eagle Pharmaceuticals Inc.'s (Nasdaq: EGRX) BENDEKA to treat chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. The stock price leaped $18.29 to close at $100.21.
FDA approves Eagle Pharmaceuticals' BENDEKA
December 08, 2015 at 15:56 PM EST
